Table 5.
C. difficile stool culture results for group 4, cohort 2
| Group and subject no. | Stool culture resulta |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predoseb (day −6) | Study drug administration days |
Follow-up days |
||||||||||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 21 | 28 | ||
| Placebo | ||||||||||||||||
| 14204 | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| 14207 | − | − | − | − | − | + (p) | + | + | + | + | + | − | − | + (p) | − | − |
| 14210 | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| VP20621 (106 spores) | ||||||||||||||||
| 14201 | − | + (n) | − | − | − | + | + | + | + | + | + | + | + | + (n) | − | − |
| 14202 | − | − | −- | − | + (n) | + | + | + | + | + | + | − | + (n) | − | + (n) | − |
| 14203 | − | + (n) | − | − | + | + | −- | + | + | + | + | + | + | + (n) | − | − |
| 14205 | − | + (n) | − | + | + | + | + | + | + | + | + | + | + | + (n) | NA | +(n) |
| 14206 | − | − | − | − | − | + (n) | + | + | + | + | + | + | + | + (n) | − | − |
| 14208 | − | − | − | − | + (n) | + | + | + | + | + | + | + | + (n) | − | − | − |
| 14209 | − | − | − | − | + (n) | + | + | + | + | + | + | + | + | + (n) | + (n) | − |
| 14211 | − | − | − | − | + (n) | + | + | + | + | − | + | + | + | + (n) | − | − |
| 14212 | − | − | − | − | + (n) | + | + | + | + | + | + | + | + | + (n) | + (n) | − |
a
Symbols and abbreviations: −, C. difficile culture negative; +, C. difficile culture positive; (n), toxin A/B negative; (p), toxin A/B positive; NA, stool sample not available; shaded cells, the isolate was confirmed to be consistent with VP20621.
b
Predose samples were collected prior to start of pretreatment with oral vancomycin.